Phase II study of vinorelbine (NVB) in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck (SCCHN)

被引：0
|
作者：
Degardin, M
Bastit, P
Rolland, F
Armand, JP
Chevallier, B
VanGlabbeke, M
Boudillet, J
Tresca, P
机构：
来源：
EUROPEAN JOURNAL OF CANCER | 1997年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：843 / 843
页数：1
相关论文
共 50 条
  • [41] A phase II trial of biweekly gemcitabine and paclitaxel (GEMTAX) combination in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN): A Southwest Oncology Group study
    Bickel, K. E.
    Worden, F. P.
    Moon, J.
    Kucuk, O.
    Wheeler, R. H.
    Clark, J.
    Wolf, G. T.
    Urba, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [42] A phase II trial of docetaxel, cisplatin and 5-fluorouracil in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN)
    Baghi, M
    Hambek, M
    Wagenblast, J
    May, A
    Wolfgang
    Gstoettner
    Knecht, R
    ANTICANCER RESEARCH, 2006, 26 (1B) : 585 - 590
  • [43] A phase II study of ifosfamide in recurrent squamous cell carcinoma of the head and neck
    Huber, MH
    Lippman, SM
    Benner, SE
    Shirinian, M
    Dimery, IW
    Dunnington, JS
    Hong, WK
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1996, 19 (04): : 379 - 383
  • [44] Phase 2 study of dalantercept in recurrent or metastatic squamous cell carcinoma of the head and neck
    Jimeno, Antonio
    Posner, Marshall R.
    Weiss, Jared
    Wirth, Lori J.
    Saba, Nabil F.
    Cohen, Roger B.
    Popa, Elizabeta C.
    Argiris, Athanassios
    Grossmann, Kenneth F.
    Sukari, Ammar
    Korth, Chris
    Wilson, Dawn
    McClure, Ty
    Alimzhanov, Marat
    Pearsall, Scott
    Attie, Kenneth M.
    Sherman, Matthew L.
    Pandya, Shuchi Sumant
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [45] Phase II trial of cetuximab (C) and bevacizumab (B) in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN): Final results.
    Argiris, A.
    Kotsakis, A. P.
    Kim, S.
    Worden, F. P.
    Savvides, P.
    Gibson, M. K.
    Blumenschein, G. R.
    Chen, H. X.
    Grandis, J. R.
    Kies, M. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [46] Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma
    Geiger, Jessica L.
    Bauman, Julie E.
    Gibson, Michael K.
    Gooding, William E.
    Varadarajan, Prakash
    Kotsakis, Athanasios
    Martin, Daniel
    Gutkind, Jorge Silvio
    Hedberg, Matthew L.
    Grandis, Jennifer R.
    Argiris, Athanassios
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2016, 38 (12): : 1759 - 1764
  • [47] Phase II Trial of Chemotherapy, Cetuximab, and Erlotinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
    Bhatia, Aarti
    Mehra, Ranee
    Bauman, Jessica
    Khan, Saad A.
    Wei, Wei
    Neumeister, Veronique
    Sandoval-Schaefer, Teresa
    Alpaugh, R. Katherine
    Lango, Miriam
    Rimm, David L.
    Ridge, John A.
    Burtness, Barbara
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2025,
  • [48] A phase II trial of bryostatin-1 in patients with metastatic or recurrent squamous cell carcinoma of the head and neck
    Pfister, DG
    McCaffrey, J
    Zahalsky, AJ
    Schwartz, GK
    Lis, E
    Gerald, W
    Huvos, A
    Shah, J
    Kraus, D
    Shaha, A
    Singh, B
    Wolden, S
    Zelefsky, M
    Palgi, I
    INVESTIGATIONAL NEW DRUGS, 2002, 20 (01) : 123 - 127
  • [49] A Phase II Trial of Bryostatin-1 in Patients with Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
    David G. Pfister
    John McCaffrey
    Andrew J. Zahalsky
    Gary K. Schwartz
    Eric Lis
    William Gerald
    Andrew Huvos
    Jatin Shah
    Dennis Kraus
    Ashok Shaha
    Bhuvanesh Singh
    Suzanne Wolden
    Michael Zelefsky
    Ilana Palgi
    Investigational New Drugs, 2002, 20 : 123 - 127
  • [50] Phase II study of 250 mg gefitinib in advanced squamous cell carcinoma of the head and neck (SCCHN).
    Kane, MA
    Cohen, E
    List, M
    Mehrotra, B
    Gustin, D
    Mauer, A
    Cella, D
    Vokes, E
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 509S - 509S
12345